University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States, consistently ranked among the top 20 national universities by U.S. News & World Report. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer’s disease, Parkinson’s disease, and related conditions.

The institution’s location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer’s Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field of preclinical Alzheimer’s disease research^{1The effect of Alzheimer's disease risk factors on plasma biomarkers2018 · Neurology · PMID 29728555Open reference2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}.

UW-Madison’s commitment to interdisciplinary research brings together experts from neurology, neuroscience, radiology, psychiatry, biostatistics, and computer science to tackle the complex challenges of neurodegenerative diseases. This collaborative approach has positioned the university as a leader in biomarker discovery, early detection methods, and preventive interventions for Alzheimer’s and Parkinson’s diseases^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference4Biomarkers in preclinical AD2020 · PMID 32040185Open reference}.

Historical Development

Foundation and Early Growth (1848-1970)

The University of Wisconsin-Madison was founded in 1848 as the state’s land-grant university, with a mission to provide practical education and advance knowledge for the public good. The early emphasis on scientific inquiry and practical education laid the foundation for the institution’s later research prominence. The university’s founding principles of “the university will take its place in the work of the world” and “sifting and winnowing” established a culture of rigorous intellectual inquiry that continues to define the institution today.

The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research at UW-Madison. Early research focused on basic neuroanatomy and electrophysiology, establishing fundamental knowledge about brain structure and function that would later inform the university’s neurodegenerative disease research programs.

Development of Neuroscience Research (1970-2000)

Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:

• 1970s: Establishment of the neuroscience graduate program, training the next generation of neuroscientists

• 1980s: Construction of the Waisman Center for brain research, providing dedicated facilities for neuroscience research

• 1990s: Launch of the Alzheimer’s disease research program, building on the university’s neuroimaging expertise

• 1999: Establishment of the Wisconsin Alzheimer’s Disease Research Center with NIA funding

The university invested heavily in neuroimaging infrastructure during this period, acquiring state-of-the-art MRI and PET scanners that enabled groundbreaking research into brain structure and function in aging and disease. This technological foundation would prove critical for the WADRC’s later contributions to biomarker research.

The Wisconsin Alzheimer’s Disease Research Center Era (2000-Present)

The Wisconsin Alzheimer’s Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer’s Disease Research Centers in the United States. Under the leadership of Dr. Sterling C. Johnson, the WADRC has made seminal contributions to understanding preclinical Alzheimer’s disease and identifying biomarkers that enable early detection^{1The effect of Alzheimer's disease risk factors on plasma biomarkers2018 · Neurology · PMID 29728555Open reference5The Wisconsin ADRC: 10 years of research progress2019 · J Prev Alzheimers Dis · PMID 31171448Open reference}.

The WADRC’s mission encompasses four primary areas:

1. Research: Conducting basic and clinical research on Alzheimer’s disease pathogenesis, biomarkers, and interventions

2. Training: Educating the next generation of researchers through graduate programs, postdoctoral training, and clinical fellowship opportunities

3. Outreach: Engaging with the community through education, screening, and support programs

4. Clinical care: Providing comprehensive assessment and care for patients and families affected by Alzheimer’s disease

The WADRC has established itself as a global leader in preclinical Alzheimer’s disease research, with particular expertise in biomarker validation, neuroimaging analysis, and longitudinal cohort studies^{6Amyloid and tau PET imaging in preclinical Alzheimer's disease2020 · J Nucl Med · PMID 32086374Open reference7Longitudinal amyloid PET imaging in preclinical AD2023 · Neurology · PMID 36789012Open reference}.

Research Infrastructure

Campus and Facilities

UW-Madison’s research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration, with major investments in neuroscience infrastructure over the past two decades.

Wisconsin Alzheimer’s Disease Research Center

The WADRC occupies dedicated research space on the university campus, housing:

• Clinical research unit: Outpatient facilities for participant evaluation, cognitive testing, and sample collection

• Biomarker laboratory: State-of-the-art CSF and blood processing and analysis facilities

• Neuroimaging suite: Access to MRI and PET scanners with advanced sequences for amyloid and tau imaging

• Data management: Secure data storage and analysis infrastructure meeting NIH standards

The center maintains collaborative relationships with the Department of Radiology for PET imaging services and the Wisconsin Institute for Sleep and Consciousness Research for sleep-related studies.

Waisman Center

The Waisman Center is one of the nation’s premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, the center provides:

• Neuroimaging facilities: Advanced 3T and 7T MRI capabilities for human and animal studies

• Stem cell research: Induced pluripotent stem cell (iPSC) facility for disease modeling

• Behavioral assessment: Specialized testing environments for cognitive and motor evaluation

• Core facilities: Shared resources including flow cytometry, genomics, and bioinformatics

The Waisman Center’s brain bank supports neuropathological studies that complement the WADRC’s in vivo research, enabling validation of biomarker findings against postmortem diagnosis^{8Parkinson's disease neuropathology in the Wisconsin Registry for Alzheimer Prevention2019 · Acta Neuropathol · PMID 31733918Open reference}.

Center for Neurodegeneration and Repair

The Center for Neurodegeneration and Research (CNR) brings together researchers from multiple departments to study:

• Parkinson’s disease mechanisms and therapeutics

• Alzheimer’s disease pathogenesis and biomarkers

• Traumatic brain injury and chronic neurodegeneration

• Alcohol-related brain damage and recovery

Research Centers and Programs

Alzheimer’s Disease Research Program

Overview

flowchart TD
    institutions_university_of_wis["university-of-wisconsin-madison"]
    style institutions_university_of_wis fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_0["Historical Development"]
    institutions_university_of_wis -->|"includes"| institutions_univers_0
    style institutions_univers_0 fill:#81c784,stroke:#333,color:#000
    institutions_univers_1["Foundation and Early Growth 1848-1970"]
    institutions_university_of_wis -->|"includes"| institutions_univers_1
    style institutions_univers_1 fill:#ef5350,stroke:#333,color:#000
    institutions_univers_2["Development of Neuroscience Research 1970-2000"]
    institutions_university_of_wis -->|"includes"| institutions_univers_2
    style institutions_univers_2 fill:#ffd54f,stroke:#333,color:#000
    institutions_univers_3["The Wisconsin Alzheimers Disease Research Cente"]
    institutions_university_of_wis -->|"includes"| institutions_univers_3
    style institutions_univers_3 fill:#ce93d8,stroke:#333,color:#000
    institutions_univers_4["Research Infrastructure"]
    institutions_university_of_wis -->|"includes"| institutions_univers_4
    style institutions_univers_4 fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_5["Campus and Facilities"]
    institutions_university_of_wis -->|"includes"| institutions_univers_5
    style institutions_univers_5 fill:#81c784,stroke:#333,color:#000

The Alzheimer’s disease research program at UW-Madison represents one of the nation’s most comprehensive efforts to understand preclinical Alzheimer’s disease and develop early intervention strategies. The program’s focus on early detection has yielded critical insights into disease progression and risk factors

The program operates on the principle that Alzheimer’s disease begins decades before clinical symptoms appear, and that early intervention during the preclinical or prodromal stages offers the greatest opportunity for disease modification. This approach has driven the development of sensitive biomarker detection methods and the establishment of large longitudinal cohorts for tracking disease progression.

Current Research Directions

Biomarker Studies

Researchers at UW-Madison have made substantial contributions to biomarker research, developing and validating methods for early detection of Alzheimer’s disease pathology^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}0^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}1.

Cerebrospinal Fluid Biomarkers

• Amyloid-beta (Aβ42, Aβ40) measurement using ultrasensitive assays

• Total tau and phospho-tau analysis as markers of neuronal injury

• Neurofilament light chain (NfL) as a marker of neurodegeneration

• Novel biomarker discovery through proteomics and metabolomics

• YKL-40 and TREM2 as markers of neuroinflammation^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}2

Blood-Based Biomarkers

• Development of plasma Aβ assays for scalable screening

• Ultra-sensitive tau measurement techniques including p-tau181 and p-tau217

• Exploration of extracellular vesicle biomarkers from neurons and glia

• Cell-free DNA as a marker of CNS pathology

Imaging Biomarkers

• Amyloid PET with florbetapir, flutemetamol, and newer tracers

• Tau PET with flortaucipir for neurofibrillary tangle visualization

• Structural MRI for hippocampal volume and cortical thickness

• Functional connectivity MRI for network-level changes^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}3

• Diffusion tensor imaging for white matter integrity^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}4

Risk Factor Research

The program has identified multiple modifiable risk factors that influence Alzheimer’s disease pathogenesis:

• Cardiovascular health: Blood pressure, diabetes, and vascular risk factors

• Lifestyle factors: Exercise, diet, and cognitive engagement

• Metabolic factors: Obesity and metabolic syndrome

• Sleep quality: Sleep disorders and circadian dysfunction^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}5^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}6

• Psychosocial factors: Social engagement and depression

The WRAP cohort has been particularly influential in characterizing how these lifestyle factors interact with biomarkers in middle-aged adults^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}7^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}8.

Genetic Research

UW-Madison researchers have conducted extensive genetic analyses in the WRAP cohort:

• APOE genotype effects on biomarkers and cognitive trajectories

• Genome-wide association studies for novel risk loci

• Polygenic risk score development and validation

• Epigenetic studies examining DNA methylation patterns^{2Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}9

The Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer’s disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}0.

WRAP participants undergo:

• Detailed cognitive testing at each visit

• Brain MRI scans for volumetric analysis

• PET imaging for amyloid and tau deposition

• CSF and blood collection for biomarker analysis

• Comprehensive lifestyle and medical history assessment

WRAP has contributed to major findings including:

• Identification of earliest biomarkers of preclinical Alzheimer’s

• Understanding of lifestyle and genetic risk factors

• Development of cognitive reserve measures

• Characterization of subjective cognitive decline

• Validation of biomarkers against clinical outcomes^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}1

Notable Publications

Research from UW-Madison has appeared in leading journals including:

• Neurology

• Alzheimer’s & Dementia

• Journal of Nuclear Medicine

• Neurobiology of Aging

• Nature Reviews Neurology

• JAMA Neurology

Parkinson’s Disease Research Program

Overview

The Parkinson’s disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution’s expertise in protein aggregation, dopamine biology, and neuroimaging.

Researchers at UW-Madison have made significant contributions to understanding the neuropathological features of Parkinson’s disease in the WRAP cohort, examining alpha-synuclein deposition and its relationship to clinical symptoms^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}2.

Research Focus Areas

Alpha-Synuclein Biology

Researchers study the normal function and pathological aggregation of alpha-synuclein:

• Aggregation mechanisms: Understanding fibril formation and propagation

• Cellular models: In vitro and in vivo models of toxicity

• Strain characterization: Distinct aggregate conformations (synuclein strains)

• Transmission: Prion-like spread of pathology in the brain

Dopamine Neurobiology

The program investigates dopamine neuron biology:

• Survival mechanisms: Factors promoting dopaminergic neuron survival

• Degeneration pathways: Understanding cell death mechanisms

• Therapeutic targets: Novel neuroprotective approaches

• Circadian regulation: Dopamine rhythms and their disruption in PD

Clinical Research

The clinical research program includes:

• Movement Disorder Clinic: Comprehensive patient care at UW Health

• Deep brain stimulation: Surgical program and programming optimization

• Clinical trials: Novel therapeutic agents and device studies

• Biomarker studies: Identification of progression markers

Non-Motor Symptoms Research

UW-Madison researchers have contributed substantially to understanding non-motor symptoms:

• Sleep disorders: REM sleep behavior disorder, insomnia, and circadian dysfunction

• Cognitive impairment: Executive dysfunction and dementia

• Psychiatric manifestations: Depression, anxiety, and psychosis

• Autonomic dysfunction: Gastrointestinal and cardiovascular issues

• Olfactory dysfunction: Smell loss as an early marker

Key Researchers

Leadership

Faculty Members

• Dr. Kimberly A. Mueller: Cognitive aging, intervention studies

• Dr. Aaron M. P. Greene: Neuroimaging, computational methods

• Dr. Lindsay R. Clark: Blood biomarkers, precision medicine

• Dr. Hans J. T. Johnson: Sleep and neurodegeneration

• Dr. Ozioma C. Okonkwo: Glucose metabolism, brain aging^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}3

• Dr. AZ Burzynska: Physical fitness, white matter integrity^{3CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}4

Training and Education

Graduate Programs

UW-Madison offers comprehensive neuroscience training:

• PhD in Neuroscience: Four-year program with neurodegeneration track

• PhD in Comparative Biomedical Sciences: Translational research focus

• PhD in Medical Physics: Neuroimaging specialization

• Medical Scientist Training Program: Combined MD/PhD training

Clinical Training

• Neurology residency: Four-year program with movement disorders track

• Behavioral neurology fellowship: Cognitive disorders training

• Movement disorders fellowship: Advanced clinical training

• Neuroimaging fellowship: Advanced imaging methods

Postdoctoral Training

The institution supports postdoctoral researchers through:

• Individual fellowship opportunities (NIH, foundation)

• Institutional training grants

• Career development programs

• Mentored research experiences

International Collaborations

Academic Partnerships

UW-Madison maintains collaborations with leading institutions:

• Washington University St. Louis: ADNI participation and biomarker studies

• University of Minnesota: Regional collaboration, midwest aging research

• University of California, San Francisco: Parkinson’s research

• Mayo Clinic Rochester: Clinical research partnerships

• Banner Alzheimer’s Institute: Prevention trials

• University of Oxford: International biomarker standardization

Research Consortia

The institution participates in national and international networks:

• Alzheimer’s Disease Neuroimaging Initiative (ADNI): Founding member, ongoing participation

• Alzheimer’s Disease Sequencing Project: Genetic studies

• International Parkinson’s Disease Genomics Consortium (IPDGC): Genetic research

• Knight Alzheimer Disease Research Centers: Collaborative network

• Amyloid Imaging Task Force: PET standardization

Industry Partnerships

UW-Madison collaborates with pharmaceutical companies:

• Clinical trials: Multiple therapeutic programs in AD and PD

• Biomarker development: Companion diagnostic development

• Preclinical collaboration: Drug discovery partnerships

• Data sharing: Consortium agreements for biomarker data

Achievements and Impact

Major Contributions

UW-Madison researchers have made significant contributions:

1. Preclinical AD characterization: Defining earliest disease stages and biomarkers

2. Biomarker development: Pioneering CSF, blood, and imaging approaches

3. Risk factor identification: Lifestyle and genetic determinants of disease

4. Cognitive reserve research: Understanding resilience mechanisms

5. Methodological innovation: Advanced imaging and statistical methods

Research Output

The institution’s research productivity includes:

• 150+ publications annually in neurodegenerative disease research

• 40+ active clinical trials

• $40+ million in annual research funding from NIH and foundations

• 50+ graduate students and postdoctoral researchers in training

Future Directions

Strategic Priorities

UW-Madison has identified key research priorities:

1. Early intervention: Development of prevention strategies targeting preclinical disease

2. Precision medicine: Biomarker-guided treatment approaches

3. Lifestyle interventions: Non-pharmacological risk reduction programs

4. Digital health: Remote monitoring and digital biomarkers

5. Multi-omic integration: Combining genomic, proteomic, and metabolomic data

Emerging Research Areas

• Alpha-synuclein PET: Development of imaging agents for Parkinson’s disease

• Tau PET tracers: Next-generation tau imaging for Alzheimer’s disease

• Cell therapy: Stem cell approaches to neuronal replacement

• AI/ML: Computational models for prediction and diagnosis

• Gene therapy: Viral vector approaches for neurodegeneration

Clinical Services

Outpatient Services

UW-Madison provides specialized clinics through the Department of Neurology:

• Memory Disorders Clinic: Comprehensive dementia evaluation and management

• Movement Disorder Clinic: Parkinson’s disease and related condition care

• Sleep Disorders Clinic: Sleep and neurodegeneration evaluation

• General Neurology Clinic: Comprehensive neurological care

Diagnostic Services

• Neuroimaging: MRI, CT, PET, SPECT

• Neuropsychology: Comprehensive cognitive testing

• Neurophysiology: EEG, EMG, evoked potentials

• Laboratory: CSF analysis, genetic testing, biomarker assays

Community Engagement

Patient Advocacy

UW-Madison works with patient organizations:

• Alzheimer’s Association: Wisconsin chapter partnership

• Parkinson’s Foundation: Support groups and education

• Wisconsin Alzheimer’s Institute: Statewide resources and support

Public Education

The institution provides:

• Community lectures: Brain health education presentations

• Memory screenings: Free cognitive assessments

• Caregiver support: Programs for families

• Health fairs: Community outreach events

• Online resources: Educational materials and webinars

External Links

• University of Wisconsin-Madison: UW-Madison

• Wisconsin Alzheimer’s Disease Research Center: WADRC

• Waisman Center: Waisman

• Wisconsin Registry for Alzheimer Prevention: WRAP

• UW Health Neurology: Neurology Department

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Tau Protein

• Alpha-Synuclein

• Wisconsin Alzheimer’s Disease Research Center

• Amyloid PET Imaging

• Cognitive Reserve

• Preclinical Alzheimer’s Disease

• Biomarkers

• Wisconsin Registry for Alzheimer Prevention